Oral Versus Intravenous High-Dose Methylprednisolone for Treatment of Relapses in Patients With Multiple Sclerosis (COPOUSEP): A Randomised, Controlled, Double-Blind, Non-Inferiority Trial
The Lancet - United Kingdom
doi 10.1016/s0140-6736(15)61137-0
Full Text
Open PDFAbstract
Available in full text
Categories
Date
September 1, 2015
Authors
Publisher
Elsevier BV